Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesGolimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases
Formulary , 09/17/09
Phung OJ et al. – Golimumab is a human anti–tumor necrosis factor (TNF)–alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In clinical trials, subcutaneous (SC) golimumab injected every 4 weeks significantly improved clinically relevant end points in all 3 disease states. Golimumab may increase the risk for upper respiratory tract infection, lymphoma, and injection–site reaction, but the incidence of these adverse events was low in clinical trials.
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment , 12/04/09
Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus
Arthritis & Rheumatism, 12/04/09
Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
Arthritis & Rheumatism, 12/04/09
Sponsor
Article Search
Sponsor